Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient, age \>19, scheduled for breast cancer surgery under general anesthesia~Exclusion Criteria:~* Patients who are not alert before procedure~* Day surgery~* BMI ≥35~* Hemodynamicaly unstable patients before procedure~* Patients with history of neromuscular disease or drug use affecting neuromuscular function.~* Patients with history of adverse reaction of allergic reaction to study drugs~* Patients who are anticipated to be unable to remove supraglottic airway or endotracheal tube due to severe dyspnea or need for mechanical ventilatory support~* Use of sedatives (anxiolytics, psychoactive medication, antidepressants, hypnotics) within 24 h~* Known galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption~* Alcohol or drug dependence~* Organic brain disorder~* Patients with hypersensitive to beans or peanut~* Patients who refuse to participate

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remimazolam with flumazenil (Type: EXPERIMENTAL): Patients allocated to remimazolam with flumazenil group receive remimazolam as the main anesthetics during general anesthesia and then flumazenil administration at the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
- Propofol-based total intravenous anesthesia (Type: ACTIVE_COMPARATOR): Patients allocated to the propofol-based total intravenous anesthesia group receive propofol as the main anesthetics during general anesthesia until the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).